Synonym |
Thai / English name |
Part Used : ใบActivity : HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY DECREASESolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a recommended daily in take (RDI) 250 mg, this would result in volume per dose index (VDI) of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a recommended daily in take (RDI) 250 mg, this would result in volume per dose index (VDI) of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY DECREASESolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 5.3 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY DECREASESolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 0.53 L**Duration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 34.39 +/- 4.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.3 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 4 LDuration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 33.8 +/- 3.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.
Part Used : ใบActivity : HEPATIC UDP GLUCORONOSYLTRANSFERASE ACTIVITY DECREASESolvent/Active Compound : Methanol, catechin epigallocatechin gallate (EGCG)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Dose in 4 LDuration : -Type of interaction : PharmacokineticsInteraction with drug : TrifluroperazineDose/Conc.(drug) : 60 micromolarResult : PositiveRemark : Results: EGCG inhibited trifluoperazine glucoronide (UGT1A4) in human liver microsome with Rough IC50 values of 33.8 +/- 3.1 microgram/ml. For a RDI 250 mg, this would result in VDI of 7.4 I/dose.Note : Type of experiment: *Human liver microsomal (HLM) **Working solutions were freshly prepared so that final herbal concentrations in screening incubations would represent the recommended daily intake of each extract in 53, 5.3, and 0.53 liters. Each herbal extract was coincubated at three concentrations with trifluoperazine (for UGT1A4), serotonin (for UGT1A6), and mycophenolic acid (for UGT1A9) and human liver microsome. Formation of trifluoperezine glucoronide, serotonin glucuronide, and mycophenolic acid beta-D- glucoronide were used as index reactions for activity of UGT1A4, UGT1A6, and UGT1A9 enzyme activities, respectively.